

General information about company	
Scrip code	531592
NSE Symbol	
MSEI Symbol	
ISIN*	INE861N01036
Name of company	Genpharmasec Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2023
Date of end of financial year	31-03-2024
Date of board meeting when results were approved	11-08-2023
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	03-08-2023
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	11-08-2023 15:00
End date and time of board meeting	11-08-2023 16:20
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-06-2023	30-06-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	596.4	596.4
	Other income	11.19	11.19
	Total income	607.59	607.59
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	615.96	615.96
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-173.21	-173.21
(d)	Employee benefit expense	19.79	19.79
(e)	Finance costs	6.29	6.29
(f)	Depreciation, depletion and amortisation expense	0.7	0.7
(f)	Other Expenses		
1	Others	131.6	131.6
10			
	Total other expenses	131.6	131.6
	Total expenses	601.13	601.13

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-06-2023	30-06-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	6.46	6.46
4	Exceptional items	0	0
5	Total profit before tax	6.46	6.46
7	Tax expense		
8	Current tax	0	0
9	Deferred tax	3.84	3.84
10	Total tax expenses	3.84	3.84
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	2.62	2.62
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	2.62	2.62

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-06-2023	30-06-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss		
1	Items that will not be reclassified to profit and loss	78.33	78.33
	Total Amount of items that will not be reclassified to profit and loss	78.33	78.33
2	Income tax relating to items that will not be reclassified to profit or loss		
		0	0
3	Amount of items that will be reclassified to profit and loss		
1	Items that will be reclassified to profit and loss	0	0
	Total Amount of items that will be reclassified to profit and loss	0	0
4	Income tax relating to items that will be reclassified to profit or loss		
		0	0
5	Total Other comprehensive income	78.33	78.33

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2023	01-04-2023
B	Date of end of reporting period	30-06-2023	30-06-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	80.95	80.95
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	2768.6	2768.6
	Face value of equity share capital	1	1
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	0	0
	Diluted earnings (loss) per share from continuing operations	0	0
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	0	0
	Diluted earnings (loss) per share from continuing and discontinued operations	0	0
30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
33	Disclosure of notes on financial results		

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2023	01-04-2023
Date of end of reporting period		30-06-2023	30-06-2023
Whether accounts are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)		
	(net sale/income from each segment should be disclosed)		
1	Pharmaceuticals	596.4	596.4
2	Trading in Securities	0	0
	Total Segment Revenue	596.4	596.4
	Less: Inter segment revenue	0	0
	Revenue from operations	596.4	596.4
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each segment		
1	Pharmaceuticals	-2.69	-2.69
2	Trading in Securities	58.22	58.22
	Total Profit before tax	55.53	55.53
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income	49.07	49.07
	Profit before tax	6.46	6.46
3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
1	Pharmaceuticals	1401.27	1401.27
2	Trading in Securities	129.15	129.15
	Total Segment Asset	1530.42	1530.42
	Un-allocable Assets	716.72	716.72
	Net Segment Asset	2247.14	2247.14
4	Segment Liabilities		
	Segment Liabilities		
1	Pharmaceuticals	180.21	180.21
2	Trading in Securities	0	0
	Total Segment Liabilities	180.21	180.21
	Un-allocable Liabilities	2066.92	2066.92
	Net Segment Liabilities	2247.13	2247.13
	Disclosure of notes on segments		

